Roberta Elisa Rossi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9196233/publications.pdf

Version: 2024-02-01

52 papers 2,054 citations

331670 21 h-index 243625 44 g-index

52 all docs 52 docs citations

times ranked

52

3578 citing authors

#	Article	IF	CITATIONS
1	Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance. World Journal of Gastroenterology, 2022, 28, 1123-1138.	3.3	16
2	Functional Neuroimaging in Irritable Bowel Syndrome: A Systematic Review Highlights Common Brain Alterations With Functional Movement Disorders. Journal of Neurogastroenterology and Motility, 2022, 28, 185-203.	2.4	15
3	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. Journal of Clinical Medicine, 2022, 11, 2658.	2.4	3
4	The Role of Diet and Supplements in the Prevention and Progression of COVID-19: Current Knowledge and Open Issues. Preventive Nutrition and Food Science, 2022, 27, 137-149.	1.6	3
5	The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues. Journal of Clinical Medicine, 2022, $11,3794.$	2.4	12
6	Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are. World Journal of Gastroenterology, 2022, 28, 3258-3273.	3.3	13
7	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. Digestive and Liver Disease, 2021, 53, 367-374.	0.9	12
8	Circulating Biochemical Markers of Gastro-Entero-Pancreatic (GEP) Neuroendocrine Neoplasms (NENs)., 2021,, 55-74.		0
9	Thrombotic risk in gastroenteropancreatic neuroendocrine tumor patients: a single-center experience. Annals of Gastroenterology, 2021, 34, 588-593.	0.6	О
10	Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. Journal of Endocrinological Investigation, 2021, 44, 2227-2234.	3.3	13
11	Improved management of grade B biliary leaks after complex liver resections using gadoxetic acid disodium–enhanced magnetic resonance cholangiography. Surgery, 2021, 170, 499-506.	1.9	2
12	Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors. Transplantation, 2021, 105, 2579-2586.	1.0	13
13	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. Clinical Lung Cancer, 2021, 22, 161-169.	2.6	17
14	Neuroendocrine liver metastases treatment strategies: a viewpoint. Hepatobiliary Surgery and Nutrition, 2021, 10, 561-563.	1.5	0
15	Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World Journal of Gastroenterology, 2021, 27, 5890-5907.	3.3	26
16	Double-Balloon Enteroscopy in Detecting Small-Bowel Neuroendocrine Neoplasms: A Single-Center Prospective Study. Digestion, 2021, 102, 722-730.	2.3	4
17	Neuroendocrine Neoplasms (NENs). UNIPA Springer Series, 2021, , 1061-1089.	0.1	O
18	Response and relapse rates after treatment with longâ€acting somatostatin analogs in multifocal or recurrent typeâ€1 gastric carcinoids: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2020, 8, 140-147.	3.8	17

#	Article	IF	CITATIONS
19	Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. Journal of Clinical Medicine, 2020, 9, 2468.	2.4	11
20	New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. Cells, 2020, 9, 688.	4.1	58
21	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. Oncologist, 2020, 25, 259-265.	3.7	27
22	COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. The Lancet Gastroenterology and Hepatology, 2020, 5, 532-533.	8.1	217
23	Adjuvant radiotherapy in urothelial neuroendocrine carcinoma. Minerva Chirurgica, 2020, 75, 210-212.	0.8	0
24	Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms. Pancreas, 2018, 47, 1249-1255.	1.1	35
25	Intraductal papillary mucinous neoplasms of the pancreas: a clinical challenge. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1123-1133.	3.0	13
26	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. Annals of Surgical Oncology, 2018, 25, 3200-3206.	1.5	39
27	Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity. Scandinavian Journal of Gastroenterology, 2018, 53, 835-842.	1.5	29
28	ASO Author Reflections: Heterogeneity of Duodenal Neuroendocrine Tumors. Annals of Surgical Oncology, 2018, 25, 858-859.	1.5	1
29	Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin. Internal and Emergency Medicine, 2018, 13, 1089-1091.	2.0	6
30	Endoscopic techniques to detect smallâ€bowel neuroendocrine tumors: A literature review. United European Gastroenterology Journal, 2017, 5, 5-12.	3.8	27
31	Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scandinavian Journal of Gastroenterology, 2016, 51, 513-523.	1.5	22
32	A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival. Oncotarget, 2016, 7, 18978-18983.	1.8	21
33	Hepatic Hemangioma in Celiac Patients: Data from a Large Consecutive Series. Gastroenterology Research and Practice, 2015, 2015, 1-6.	1.5	9
34	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of Oncology, 2015, 26, 1604-1620.	1.2	514
35	Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: Overview of available evidence and open issues. Digestive and Liver Disease, 2015, 47, 819-825.	0.9	64
36	Goblet cell appendiceal tumors – Management dilemmas and long-term outcomes. Surgical Oncology, 2015, 24, 47-53.	1.6	41

#	Article	IF	Citations
37	Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Annals of Translational Medicine, 2015, 3, 118.	1.7	14
38	Currently neglected, physical examination maintains its clinical relevance. Internal and Emergency Medicine, 2014, 9, 871-874.	2.0	1
39	Liver Transplantation for Unresectable Neuroendocrine Tumor Liver Metastases. Annals of Surgical Oncology, 2014, 21, 2398-2405.	1.5	51
40	Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutrition and Metabolism, 2014, 11, 30.	3.0	84
41	Chromogranin A in Diagnosing and Monitoring Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Large Series from a Single Institution. Neuroendocrinology, 2014, 100, 240-249.	2.5	72
42	Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World Journal of Gastroenterology, 2014, 20, 17352.	3.3	50
43	Therapy for metastatic pancreatic neuroendocrine tumors. Annals of Translational Medicine, 2014, 2, 8.	1.7	29
44	Nutrition and pancreatic cancer. Anticancer Research, 2014, 34, 9-21.	1.1	139
45	The role of dietary factors in prevention and progression of breast cancer. Anticancer Research, 2014, 34, 6861-75.	1.1	53
46	Nutritional deficiencies in inflammatory bowel disease: Therapeutic approaches. Clinical Nutrition, 2013, 32, 904-910.	5.0	126
47	Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. European Journal of Endocrinology, 2013, 168, 755-761.	3.7	30
48	Transient elastography in patients with celiac disease: A noninvasive method to detect liver involvement associated with celiac disease. Scandinavian Journal of Gastroenterology, 2012, 47, 640-648.	1.5	4
49	Unusually aggressive type 1 gastric carcinoid. European Journal of Gastroenterology and Hepatology, 2012, 24, 589-593.	1.6	31
50	Treatment of Liver Metastases in Patients with Digestive Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2012, 16, 1981-1992.	1.7	13
51	Response to Wiwanitkit. American Journal of Gastroenterology, 2010, 105, 2702.	0.4	0
52	Plasma Chromogranin A Response to Octreotide Test: Prognostic Value for Clinical Outcome in Endocrine Digestive Tumors. American Journal of Gastroenterology, 2010, 105, 2072-2078.	0.4	57